Topics

Fight for Sight Company Profile

22:45 EDT 28th March 2020 | BioPortfolio

Since 1946, Fight for Sight (FFS) has invested in the future of eye and vision research by funding promising scientists early in their careers. FFS has supported over 3,000 new scientists with more than $20 million in research that has contributed directly or indirectly to major advances in ophthalmology and vision research, including development of the IOL, aspects of donor cornea preservation, various uses of ophthalmic lasers, glaucoma therapies, and gene therapy. Founder Mildred Weisenfeld lost her vision to retinitis pigmentosa before starting Fight for Sight, the first organization to promote the importance of funding eye research.


News Articles [691 Associated News Articles listed on BioPortfolio]

Fight for Sight to fund macular degeneration research

As it stands, damage to the macula can’t be reversed, making it the most common cause of permanent and severe sight loss in the UK.

Sight Sciences secures $30m funding for eye disease treatment products

US-based medical device company Sight Sciences has secured $30m in a Series E preferred stock financing round to commercialise its Omni and TearCare products. Based in California, Sight The post Sigh...

1/3 of people with sight loss suffer mental health problems

84% of Brits fear losing their sight more than any other sense.

Unlike Theranos: FDA Clears Sight Diagnostics’ Finger-Prick Blood Test for U.S. Market

– Sight Diagnostics, the company working to provide patients with lab-grade blood testing results in minutes, has received US FDA 510(k) clearance for its finger-prick blood test, OLO analyzer t...

Sight Sciences secures £45.6m funding for glaucoma and dry eye products

Medical device company Sight Sciences has secured in $56m (£45.6m) in new funding to speed up the growth of its OMNI Surgical System and TearCare System in the The post Sight Sciences secures £45.6...

GenSight Biologics Announces its 2020 Financial Calendar

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for r...

GenSight Biologics Announces the Filing of its 2018 Universal Registration Document

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for r...

Research examines role of Nicotinamide in preventing retinal cell damage caused by glaucoma

Fight for Sight is funding researchers at Cardiff University to examine the extent to which dietary supplementation of Nicotinamide – a form of vitamin B3 – can be used to reduce, and even prevent...

Drugs and Medications [71 Associated Drugs and Medications listed on BioPortfolio]

Sodium chloride [baxter healthcare corporation]

Sodium Chloride 0.9% w/v Intravenous Infusion, BP, in VIAFLO container

Heparin sodium and sodium chloride [baxter healthcare corporation]

Heparin Sodium bp 2000 iu/l in0.9% w/v sodium chloride iv infusion

Sodium chloride [baxter healthcare corporation]

Sodium Chloride Intravenous Infusion BP 0.9% w/v

Metronidazole [baxter healthcare corporation]

Metronidazole 500 mg/100 ml Intravenous Infusion

Synthamin [baxter healthcare corporation]

SYNTHAMIN 17 without Electrolytes

PubMed Articles [128 Associated PubMed Articles listed on BioPortfolio]

Evaluating Whether Sight Is the Most Valued Sense.

Sight is often considered to be the sense most valued by the general public, but there are limited empirical data to support this. This study provides empirical evidence for frequent assertions made b...

Eye-Hand Span is not an Indicator of but a Strategy for Proficient Sight-Reading in Piano Performance.

Eye-hand span, i.e., the distance between a performer's fixation and execution of a note, has been regarded as a decisive indicator of performers' competence in sight-reading. However, integrated pers...

The Impact on Work Patterns of Implementing the Save Sight Keratoconus Registry in the Hospital Setting.

The adoption of clinical registries has the potential to improve outcomes, while reducing the costs of health care. We sought to evaluate the changes in workflow that occurred with implementation of t...

Fight or flight: The culprit is lurking in the neighbourhood.

The fight-or-flight response is studied by all students of Physiology as a concerted bodily response to danger. Liu et al (2020) have now revealed its mechanism, after surveying the proteomic neighbou...

Adult Presentation of X-Linked Retinoschisis: Patient and Physician Perspectives.

This commentary article is co-authored by an adult patient with X-linked retinoschisis and two ophthalmologists affiliated with the University Hospitals Birmingham NHS Foundation Trust. It describes t...

Clinical Trials [636 Associated Clinical Trials listed on BioPortfolio]

Investigating Usability of c-SIGHT in the Homes of Brain Injury Survivors With Spatial Neglect

A stroke can damage the brain, so that it no longer receives information about the space around one side of the world. If this happens, people may not be aware of anything on one side, usu...

Pre-Competition Carbohydrate Supplementation

The objective of the present study was to evaluate the MPF and the perception of effort of professional jiu jitsu athletes from carbohydrate intake at different moments. Twelve jiu jitsu a...

IRIS Registry: Intelligent Research in Sight Registry

The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of th...

Immune Activity Against CVM Retinitis

This study will investigate whether medication for cytomegalovirus (CMV) retinitis-a viral infection of the eye-can safely be stopped in HIV-infected patients whose immune function has imp...

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease a...

Companies [227 Associated Companies listed on BioPortfolio]

Fight for Sight

Since 1946, Fight for Sight (FFS) has invested in the future of eye and vision research by funding promising scientists early in their careers. FFS has supported over 3,000 new scientists with more th...

Second Sight Medical Products, Inc.

Second Sight Medical Products, Inc., located in Los Angeles, California, was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal...

Second Sight Medical Products Inc.

Second Sight Medical Products Inc., located in Los Angeles, California, was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal ...

Second Sight

Second Sight, located in Sylmar, California, was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa and ...

Sight Machine Inc.

With dual headquarters in San Francisco and Ann Arbor, Mich., Sight Machine brings advanced Big Data and visual analytics technologies to the factory floor, helping manufacturers ...

More Information about "Fight for Sight" on BioPortfolio

We have published hundreds of Fight for Sight news stories on BioPortfolio along with dozens of Fight for Sight Clinical Trials and PubMed Articles about Fight for Sight for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fight for Sight Companies in our database. You can also find out about relevant Fight for Sight Drugs and Medications on this site too.

Quick Search

Relevant Topics

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record